Drug Trial Radar · NCT04064632
RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection
Last checked: Nov 19, 2026Latest source record: Aug 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,609
Actual
Start
Feb 1, 2017
Primary completion
Jun 13, 2019
Study completion Nov 30, 2019
Sponsor
- Lead sponsor
- A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- San Raffaele University Hospital, Italy
- First posted
- Aug 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates efficacy and safety of rilpivirine as substitutive agent for the nucleosidic backbone of HAART in virologic suppressed patients when combined with cobicistat-boosted darunavir.
Conditions
- HIV Infection
Interventions
Rilpivirine + darunavir/cobicistatDrug
Switch to a dual ART
Primary outcomes
What the sponsor says the trial is designed to measure.
- clinical responseTime frame: 24 weeks
- Virological responseTime frame: 24 weeks
- clinical responseTime frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Antiviral Therapy Unit, Ospedali Riuniti
Bergamo, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.